Many companies are opting to rapidly pivot into new product lines or significantly increase their production volumes. In doing this, they are relying on exceptions to, and derogations from, the usual regulatory regimes, or a flexible approach to enforcement by regulatory authorities – all motivated by the unique context of COVID-19.
With these changes in production, companies should pause to reflect on the longer-term considerations. We will be reviewing some of these considerations and discussing possible implications.
- What types of issues might arise
- How to avoid these issues altogether
- If issues do arise, how to resolve them quickly
- How to manage the costs associated with these issues
We encourage attendees to join ready with questions for our panelists or submit questions ahead of time.
Date & Timings:
Tuesday 5th May
8:00 am – 9:00 am PDT
11:00 am – 12:00 pm EDT
4:00 pm – 5:00 pm BST
5:00 pm – 6:00 pm CEST
Rod Freeman – Cooley
Richard Hopley – Cooley
Sarah-Jane Dobson – Cooley
Andrew Barr – Cooley